Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Kidney disease diagnostics group Renalytix AI announced that a study had indicated its flagship KidneyIntelX test accurately predicted progression of diabetic kidney disease.
Progression was predicted in a multinational cohort from the CANagliflozin CardioVAScular Assessment Study.
'The clinical outcome data suggests that KidneyIntelX risk assessment could support primary care physicians in making appropriate therapeutic intervention decisions with early-stage DKD patients to effectively delay progression and reduce the risk of adverse events,' the company said.
At 9:13am: (LON:RENX) Renalytix Ai PLC share price was 0p at 436p